McKesson (NYSE:MCK) Issues Earnings Results, Beats Estimates By $0.15 EPS

McKesson (NYSE:MCK) issued its quarterly earnings results on Wednesday. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15, FiscalAI reports. The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%. McKesson updated its FY 2026 guidance to 38.800-39.200 EPS.

McKesson Price Performance

Shares of MCK stock traded down $31.54 during trading on Wednesday, reaching $819.58. The company’s stock had a trading volume of 1,707,183 shares, compared to its average volume of 644,476. The company has a market capitalization of $101.16 billion, a price-to-earnings ratio of 25.51, a P/E/G ratio of 1.39 and a beta of 0.40. McKesson has a 1-year low of $570.51 and a 1-year high of $895.58. The stock’s 50-day moving average price is $826.85 and its 200 day moving average price is $776.36.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s payout ratio is currently 10.21%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MCK. Weiss Ratings reiterated a “buy (a-)” rating on shares of McKesson in a report on Monday, December 29th. Morgan Stanley reaffirmed an “overweight” rating and set a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Evercore ISI reissued an “outperform” rating and issued a $1,000.00 price objective on shares of McKesson in a report on Thursday, November 6th. Finally, Barclays began coverage on McKesson in a report on Monday, December 8th. They set an “overweight” rating and a $960.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $899.36.

Insider Activity

In related news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the sale, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $861.63, for a total transaction of $283,476.27. Following the completion of the sale, the chief accounting officer directly owned 328 shares in the company, valued at approximately $282,614.64. This represents a 50.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.08% of the company’s stock.

Institutional Trading of McKesson

A number of large investors have recently bought and sold shares of the business. State Street Corp increased its stake in McKesson by 0.9% in the 3rd quarter. State Street Corp now owns 5,750,519 shares of the company’s stock valued at $4,447,110,000 after buying an additional 51,510 shares during the period. Northern Trust Corp boosted its stake in McKesson by 0.4% in the 3rd quarter. Northern Trust Corp now owns 1,532,856 shares of the company’s stock worth $1,184,193,000 after buying an additional 6,613 shares during the last quarter. Boston Partners grew its holdings in McKesson by 6.7% in the 3rd quarter. Boston Partners now owns 1,330,953 shares of the company’s stock valued at $1,027,569,000 after buying an additional 83,357 shares during the period. Invesco Ltd. increased its stake in shares of McKesson by 2.2% during the 3rd quarter. Invesco Ltd. now owns 961,757 shares of the company’s stock valued at $742,996,000 after acquiring an additional 21,049 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of McKesson by 32.9% during the 3rd quarter. Wellington Management Group LLP now owns 618,984 shares of the company’s stock valued at $478,190,000 after acquiring an additional 153,182 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.